8-K: Medicus Pharma to Acquire Antev Ltd., Expanding Pipeline with Promising Prostate Cancer and Urinary Retention Therapies

Medicus Pharma Ltd. has entered into a definitive agreement to acquire Antev Ltd., a clinical-stage biotech company, gaining Teverelix, a next-generation GnRH antagonist, for prostate cancer and acute urinary retention, alongside its existing dermatology pipeline.

Summary

• Medicus Pharma Ltd. (Medicus) has signed a definitive securities exchange agreement to acquire all issued and outstanding shares of Antev Limited (Antev), a UK-based clinical-stage biotech company.
• The acquisition consideration includes 2,666,600 Medicus common shares, representing approximately 17% of Medicus's aggregate issued and outstanding shares, subject to a staggered 9-month lock-up and a 36-month voting rights agreement in favor of Medicus management.
• Antev shareholders are eligible to receive up to approximately US$65 million in additional contingent consideration upon achieving specific future U.S. Food and Drug Administration (FDA) Phase 2 and New Drug Application approvals.
• The transaction is anticipated to close before the end of August 2025, contingent on Antev shareholder approval and other corporate, regulatory, and third-party approvals.
• Antev's lead drug candidate, Teverelix, is a next-generation GnRH antagonist being developed for two primary indications: preventing recurrence of acute urinary retention (AURr) in men with prostate enlargement and as a hormone therapy for advanced prostate cancer (APC) patients with increased cardiovascular risk.
• For the AURr indication, Teverelix aims to be a first-in-class product, with an FDA-approved Phase 2b study designed to randomize 390 men, targeting a potential annual market opportunity exceeding US$2 billion.
• For the APC indication, Teverelix aims to be a best-in-class product for patients with increased cardiovascular risk, with an FDA-approved Phase 2b open-label study designed to recruit 40 men, targeting a potential annual market opportunity exceeding US$4 billion.
• Antev completed a Phase 1 clinical trial for Teverelix in September 2020, showing it was well tolerated with rapid testosterone suppression.
• A Phase 2a study for Teverelix in APC patients completed in February 2023 achieved its primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%), though the secondary endpoint of maintaining this rate above 90% dropped to 82.5% by Day 42.
• Medicus Pharma's wholly-owned subsidiary, SkinJect Inc., is developing D-MNA, a non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch.
• SkinJect completed a Phase 1 safety and tolerability study (SKNJCT-001) in March 2021, which met its primary objective and showed efficacy with six participants achieving complete response on histological examination.
• A Phase 2 IND clinical protocol (SKNJCT-003) for D-MNA was submitted to the FDA in January 2024, with an updated package in July 2024, for a randomized, controlled, double-blind, multicenter study initially targeting 60 subjects with nodular BCC, later increased to 90 subjects in April 2025.
• An interim analysis for SKNJCT-003 in March 2025 showed positively trending results with over 60% clinical clearance after more than 50% of targeted patients were randomized.
• Medicus has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE for D-MNA.

Sentiment

Score: 8

Explanation: The acquisition of a clinical-stage company with two FDA-approved Phase 2b assets targeting large markets, combined with positive interim data from an existing pipeline product, represents a significant strategic advancement and positive outlook for Medicus Pharma. While there are closing conditions and contingent payments, the overall news is highly favorable for pipeline expansion and future growth potential.

Positives

• Acquisition of Antev Ltd. significantly expands Medicus Pharma's pipeline with two promising clinical-stage assets, Teverelix, targeting large market opportunities in prostate cancer and acute urinary retention.
• Teverelix has FDA-approved Phase 2b study designs for both its Acute Urinary Retention (390 men) and Advanced Prostate Cancer (40 men) indications, indicating regulatory progress.
• Teverelix is positioned as a potential 'first-in-market' product for preventing recurrent acute urinary retention (AURr) and a 'best-in-class' hormone therapy for advanced prostate cancer patients with increased cardiovascular risk.
• The potential market opportunities for Teverelix are substantial, estimated at over US$2 billion annually for AURr and over US$4 billion annually for APC.
• Medicus's existing D-MNA product for basal cell skin cancer showed positively trending interim analysis results in March 2025 for its SKNJCT-003 Phase 2 study, demonstrating over 60% clinical clearance.
• The SKNJCT-003 study's participant target was increased from 60 to 90 subjects in April 2025, suggesting positive momentum or expanded scope.
• Teverelix's mechanism as a GnRH antagonist directly suppresses sex hormone production without an initial testosterone surge, potentially reducing cardiovascular risks, which is beneficial for high-risk patients.

Negatives

• The secondary endpoint of maintaining testosterone suppression above 90% by Day 42 was not met in Antev's Phase 2a study for Teverelix in advanced prostate cancer, dropping to 82.5%.
• The closing of the Antev acquisition is subject to various conditions, including Antev shareholder approval and regulatory approvals, with no assurances that it will close on the terms or timeframe currently contemplated, or at all.
• The US$65 million in additional contingent consideration for Antev shareholders is tied to future FDA Phase 2 and New Drug Application approvals, making it uncertain.

Risks

• No assurances can be given that the parties will successfully close the Antev acquisition on the terms or timeframe currently contemplated or at all.
• The potential benefits of the Antev transaction, including the development, advancement, and commercialization of Teverelix, are forward-looking and subject to known and unknown risks, uncertainties, and other factors.
• Actual results, performance, or achievements may differ materially from forward-looking statements due to various factors, including those described in Medicus Pharma's annual report on Form 10-K for the year ended December 31, 2024, and other public filings.
• The interim analysis findings for SKNJCT-003 are preliminary and may or may not correlate with the final findings of the study once completed.
• There is no assurance that the plans, intentions, or expectations upon which forward-looking statements are placed will occur, and actual results may differ materially from those anticipated.

Future Outlook

Medicus Pharma expects to close the acquisition of Antev Ltd. before the end of August 2025, subject to closing conditions. The company anticipates advancing the clinical development and commercialization of Teverelix for its target indications. Medicus also plans to continue patient recruitment for its SKNJCT-003 Phase 2 study for D-MNA and progress the SKNJCT-004 study in the UAE, aiming to potentially fast-track the D-MNA clinical development program.

Management Comments

• Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd., signed the Form 8-K.
• Carolyn Bonner, President, and Anna Baran-Djokovic, SVP Investor Relations, are listed as contacts for further information.

Industry Context

This acquisition signifies a strategic expansion for Medicus Pharma into the urology and oncology therapeutic areas, leveraging Antev's clinical-stage assets. The focus on next-generation GnRH antagonists like Teverelix, particularly for high-risk patient populations, aligns with a broader industry trend towards more targeted and safer therapies. The substantial market opportunities identified for Teverelix reflect the significant unmet medical needs in prostate cancer and acute urinary retention. Medicus's existing dermatology pipeline also indicates a diversified approach within the biotech/life sciences sector.

Comparison to Industry Standards

• Teverelix is aiming to be the first-in-class indication product for preventing recurrence of acute urinary retention (AURr) in males 45 years or older, who suffer from prostate enlargement, targeting a potential market opportunity of more than US$2 billion annually.
• Teverelix is aiming to be the best-in-class indication product for hormone therapy for advanced prostate cancer (APC) patients with increased cardiovascular (CV) risk, targeting a potential market opportunity of more than US$4 billion annually.
• Teverelix's mechanism as a GnRH antagonist, which directly suppresses sex hormone production without an initial testosterone surge, potentially offers a lower cardiac toxicity profile compared to conventional GnRH agonists, positioning it favorably for patients with existing cardiovascular conditions.

Corporate Governance

Stakeholder Impact

• Shareholders of Medicus Pharma: Potential for long-term value creation through pipeline expansion and access to large new markets, but also potential for dilution from the issuance of 2,666,600 shares.
• Securityholders of Antev Ltd.: Will become shareholders of Medicus Pharma, receiving an equity stake and potential contingent payments tied to future drug approvals.
• Patients with prostate cancer and acute urinary retention: Potential for new, improved treatment options (Teverelix) if clinical trials are successful and regulatory approvals are obtained.
• Patients with basal cell skin cancer: Continued progress on D-MNA offers hope for a novel, non-invasive treatment option.

Next Steps

• Fulfillment of closing conditions for the Antev acquisition, including obtaining Antev shareholder approval and other applicable corporate, regulatory, and third-party approvals.
• Closing of the Antev acquisition, expected before the end of August 2025.
• Continuation of the FDA-approved Phase 2b studies for Teverelix in Acute Urinary Retention (390 men) and Advanced Prostate Cancer (40 men).
• Continued patient recruitment for the SKNJCT-003 Phase 2 study for D-MNA in the United States (now targeting 90 subjects).
• Progression of the SKNJCT-004 clinical study for D-MNA in the UAE.

Key Dates

Recommendation

Keywords

Biotech, Acquisition, Prostate Cancer, Acute Urinary Retention, GnRH Antagonist, Teverelix, Basal Cell Skin Cancer, D-MNA, Clinical Stage, FDA Approval, Pharmaceuticals, Oncology, Urology, Drug Development